Angiogenesis is thought to depend on a perfectly coordinated balance between endogenous-positive and negative regulatory factors. Of these factors, the vascular endothelial growth factor (VEGF) and angiopoietins (Angs) seem to play an essential role. Recently, we reported the expression of the Ang-natural receptor, Tie2, in neoplastic astrocytic cells within gliomas. Because of the VEGF/Ang2 functional partnership together with the presence of Tie2 in gliomas, we hypothesized a role of Ang2 on the modulation of VEGF levels in these tumors. We examined the effect of Ang2 on VEGF expression in a panel of glioma cells, which showed that Ang2 inhibited VEGF expression at both mRNA and protein levels in Tie2-expressing cells, but not in Tie2-negative cells. VEGF promoter analysis showed that Ang2 regulated VEGF expression at the transcriptional level in relation to a decrease in HIF-1a expression and HIF-DNA-binding activity. Tie2 silencing by siRNA rescued the Ang2-mediated downmodulation of VEGF, suggesting an essential role for Tie2 in this regulatory loop. To our knowledge, this is the first report on the role of Ang2/Tie2 in the regulation of HIF-1a/VEGF expression, providing additional evidence of the intrinsic coordination that occurs among these factors during angiogenesis. Oncogene (2008 Oncogene ( ) 27, 1310 Oncogene ( -1314 doi:10.1038/sj.onc.1210731; published online 20 August 2007 Keywords: Tie2; angiopoietin-2; HIF-1a; VEGF; gliomas One of the features that distinguish high-grade gliomas is their ability to induce a robust angiogenic response, with glioblastoma multiforme being one of the most vascularized tumors. It is thought that angiogenesis depends on a balance between endogenous-positive and negative regulatory molecules and that all of these factors must act in a perfectly coordinated and complementary manner. Vascular endothelial growth factor (VEGF) plays an essential role in the angiogenesis associated with tumors, and angiopoietins (Angs) seem to be some of VEGF's most important partners in this process (Yancopoulos et al., 2000) . Angs serve as ligands for the Tie's, a family of receptor tyrosine kinases that were described as specific vascular growth factors. The best-characterized Angs are Ang1 and Ang2. While Ang1 is known to stabilize nascent vessels and make them leak resistant by recruiting and sustaining periendothelial support cell (Suri et al., 1998) , the pro-or antiangiogenic function of Ang2 appears to be context dependent (Maisonpierre et al., 1997; Yancopoulos et al., 2000) . Several studies have shown that this contextual behavior of Ang2 is, at least partially, dependent on VEGF levels. Ang2 appears to initiate and stimulate angiogenesis when acting together with VEGF, but to induce vessel regression in the absence of VEGF (Goede et al., 1998; Holash et al., 1999; Beck et al., 2000) . Such a coordinated effect implies the existence of certain mechanisms that both temporally and spatially govern the expression of these molecules and hence their concurrent or sequential effect on tumorigenesis. Recently, we reported the expression of Tie2 in neoplastic astrocytic cells within gliomas (Lee et al., 2006b) , suggesting the existence of regulatory Ang-dependent functions that together with the VEGF/Ang2 functional partnership during angiogenesis, prompted us to hypothesize that Ang2 modulates VEGF levels in gliomas.
To first investigate the involvement of sustained Ang2 in VEGF expression, we examined a panel of glioma cell lines that we found in previous studies to express Tie2 at different levels (Lee et al., 2006b) . Ang2 expression in U-87 MG and D-54 MG cells (Tie2 þ ) was associated with a reduction in mRNA and secreted VEGF levels but not with modified levels of another angiogenesis-related factor, fibroblast growth factor (FGF)-2 (Figures 1a-c;  Supplementary Figure 1) . However, Ang2 expression in U-251 MG cells (Tie2À) did not modify significantly VEGF-secreted levels (Figures 1a and b) . To confirm the Ang2-mediated transcriptional regulation of VEGF, we performed a standard luciferase assay. Ang2 expression in U-87 MG cells that were transfected with the 2.6-or 1.5-kb VEGF promoter-reporter construct, both of which contain the hypoxia-responsive element (HRE), caused a 40 and 60% inhibition in the VEGF promoter activity, respectively. However, no change in the VEGF promoter activity was seen when cells were transfected with the 0.35-kb VEGF promoter construct that did not Ang2 modulates VEGF expression in glioma O-H Lee et al encompass HRE (Figure 1d ). We observed a similar and dose-dependent effect in U-87 MG cells cotransfected with a mammalian Ang2 expression vector and the 1.5-kb VEGF promoter-reporter construct (Supplementary Figure 2) . Taken together these data demonstrated that Ang2 regulates VEGF expression at the transcriptional level in Tie2-expressing glioma cells. It is well known that the angiogenic activity of VEGF is tightly related to gene dosage (Ferrara and Alitalo, 1999) and that this culminates in the modulation of several endothelial cell (EC) properties. To determine whether the reduced VEGF expression in glioma cells expressing Ang2 affects the endothelial phenotype, we analysed the chemotactic activity of EC cultured in conditioned medium (CM) from glioma cells. Of particular interest, the migration of ECs was reduced by 50% in the presence of CM from Ang2-expressing U-87 MG cells (Figures 2a and b) . The reduced ability of U-87 MG/Ang2 cells to attract ECs was partially rescued by the addition of exogenous VEGF (Figures 2c  and d) . These results support the notion that Ang2 can modify the angiogenic property of glioma cells by decreasing VEGF expression.
To further understand the mechanism by which Ang2 regulates VEGF expression, we next examined the effect of Ang2 on the expression levels of a panel of VEGF transcription factors. Ang2-expressing U-87 MG cells exhibited a decrease in the expression levels of HIF-1a (Figures 3a and b) but did no change p53 expression levels (a negative regulator) or the phosphorylation levels of the p65 subunit of nuclear factor (NF)-kB (a positive regulator) (Loureiro and D'Amore, 2005) . In accordance with our previous results, HIF-1a protein level decreased by Ang2 in only the Tie2-expressing cells (Figure 3b) . Likewise, Ang2-expressing U-87 MG and D-54 MG cells exhibited attenuated HIF-1 DNA-binding activity, assessed by monitoring the binding ability of HIF-1a to consensus oligonucleotide sequences (Figure 3c ). In contrast, Ang2 did not decrease the HIF-1a nuclear protein levels or the HIF-1 DNA-binding activity in the U-251 MG cells (Figures 3b and c) . Of interest, when Ang2-transferred U-87 MG cells were placed in the upper chamber and control cells were placed in the lower chamber (Figure 4a , left panel), HIF-1a protein levels were decreased in the bottom culture, proving that the Ang2-mediated modulation of HIF-1a levels is receptor mediated (Figure 4a, right panel) . Thus, it is likely that the Ang2-mediated modulation of the HIF-1a/VEGF axis involves the presence of the Tie2 in the membrane of glioma cells. To further examine the possibility of this regulatory pathway, we silenced Tie2 expression by Figure 2 Ang2-expressing glioma cells showed a reduced ability to elicit EC migration that was rescued by vascular endothelial growth factor (VEGF). (a, b) EC migration was assayed in transwell plates as previously described (Gomez-Manzano et al., 2003) . Human umbilical vein endothelial cells (passages 2-7; Clonetics, San Diego, CA, USA) were seeded into the upper chamber. The lower chamber was filled with conditioned medium (CM, diluted 1:2 with DMEM/F-12 medium) from U-87 MG cultures that were mocktreated or treated with cytomegalovirus (CMV) or Ang2 for 30 min, washed twice and collected 48 h after infection. DMEM/F-12 medium in the lower chamber was used as control. Cells were incubated for 4 h at 371C in 5% CO 2 , and the transwell filters were fixed and stained with 0.4% crystal violet. Shown is a representative field (a). Cell numbers were expressed as fold increase in the number of migrated cells per high-power field compared with the number of cells that migrated in control media (10 random Figure 1 . After 3 days, cell lysates were subjected to western blot analysis, using antibodies against HIF-1a, p53, phospho-p65 subunit (ser 536) of nuclear factor (NF-kB), Ang2 and actin. (b, c) Ang2 expression decreased HIF-1a protein levels (b) and HIF-1a DNA-binding activity (c) in Tie2-expressing cells. Glioma cells were treated with CMV or Ang2 or were mocktreated. After 3 days, nuclear proteins were extracted using a nuclear extraction kit (Active Motif, Carlsbad, CA, USA). Nuclear HIF-1a expression was assessed by western blotting (topoisomer I, Topo I), and HIF-1a DNA-binding activity to consensus oligonucleotide sequences was determined using a TransAM HIF-1a kit (Active Motif). HIF-1a DNA-binding activity was expressed as a relative percentage to the activity present in mock-treated cells (equal to 100%). *Po0.005; **P>0.5 compared with activity in CMV-treated cultures.
Ang2 modulates VEGF expression in glioma O-H Lee et al siRNA in U-87 MG cells, as previously described (Lee et al., 2006b ). U-87 MG cells transfected with Tie2 siRNA did not show a significant decrease in secreted VEGF in response to Ang2, suggesting that the regulation of VEGF by Ang2 is mediated by Tie2 (Figure 4b ). Because several studies have shown that some of the functions of Angs require the presence of integrin b1 (Cascone et al., 2005; Hu et al., 2006) , we assessed whether the presence of a neutralizing anti-integrin b1 antibody prevented the Ang2-mediated regulation of VEGF in glioma cells. As shown in Figure 4c , blocking integrin b1 did not rescue the effect of Ang2 on VEGF levels. We conclude from these results that Ang2 is involved in regulating HIF-1a/VEGF levels and that Tie2 is an essential player in this axis. The expression of Tie2 was believed to be confined to vascular structures (Yancopoulos et al., 2000) . However, recent studies have identified Tie2 expression in nonvascular tissues, as in the hematopoietic system and in the nonvascular compartment of several types of cancer (Kukk et al., 1997; Shirakawa et al., 2002; Wang et al., 2005) . Recently, our group reported Tie2 expression in neoplastic astrocytic cells in malignant human gliomas (Lee et al., 2006b ). In addition, in the U-87-derived intracranial xenograft model, we observed the expression of Ang2 not only in the vascular structures, but also in the glioma cells within the periphery of the tumor (Lee et al., 2006a) . The presence of Tie2 in the membrane of glioma cells suggests the existence of regulatory Ang-mediated functions in these cells.
Although strong evidence of an antiangiogenic role for Ang2 was obtained in transgenic animal models (Maisonpierre et al., 1997) , other studies have shown that the overexpression of Ang2 in different tumors has a context-dependent antagonist function (Yancopoulos et al., 2000) , including gliomas (Machein et al., 2004; Hu et al., 2006; Lee et al., 2006a) . It is quite possible that the effect of Ang2 depends on differences in the VEGF levels (Goede et al., 1998; Holash et al., 1999; Beck et al., 2000) . Our data provide evidence of a complementary Membrane fractions were collected 72 h after transfection and analysed by western blotting for Tie2 protein levels as described previously (Lee et al., 2006b) . Epidermal growth factor receptor (EGFR) levels are shown for specificity (upper panel). VEGF present in CM were examined by ELISA as explained in Figure 1b . Cells were treated with siTie2 or control siRNA and 24 h later were cotreated with Ang2( þ ) or CMV(À). The levels of secreted VEGF were determined 48 h after, and expressed as a relative percentage to the levels of secreted VEGF in CMV-treated cells (equal to 100%). *P ¼ 0.01; **P>0.05 compared with CMV-treated cells. (c) U-87 MG cells were incubated 10 min with 10 mg/ml of neutralizing anti-integrin b1 antibody or immunoglobulin G (IgG), and then treated with Ang2( þ ) or CMV(À). The secreted levels of VEGF were analysed and represented as explained in (c). *Po0.001; **Po0.05 (compared with CMV-treated cells).
link between Ang2 and VEGF in which increasing Ang2 levels result in decreasing VEGF expression. This scenario would facilitate the required destabilization of the vasculature necessary for its subsequent remodeling. Since Ang2 is functioning as a contextual-dependent molecule, similar studies need to be pursued to extrapolate this data to other tissues. To our knowledge, this is the first report of the involvement of Ang2/Tie2 in the modulation of HIF-1a/ VEGF expression. Our findings suggest that Ang2 can regulate VEGF expression in a paracrine or autocrine fashion via HIF-1a, providing additional evidence of the intrinsic coordination of angiogenic factors. We propose on the basis of our findings that the Tie2 pathway in glioma cells is important in glioma angiogenesis and glioma progression, and that Ang2 may modify the angiogenic phenotypes of tumors not only by modulating directly endothelial functions but also by modulating other angiogenic factors.
